

1

2 **S1 Table. Adverse drug reactions for the overall population**

	Overall population (n=697)	
	Number (%) of patients with adverse reactions	Number of adverse reactions
Blood and lymphatic system disorders	88 (12.6)	97
Lymphopenia (Grade 4)	86 (12.3)	95
Leucopenia	2 (0.3)	2
Infections and infestations	39 (5.6)	51
Urinary tract infection	12 (1.7)	16
Zoster herpes	5 (0.7)	5
Candida infection	5 (0.7)	6
Upper respiratory tract infection	4 (5.7)	4
Oral herpes	3 (0.4)	4
Pneumonia	2 (0.3)	3
Respiratory tract infection	2 (0.3)	2
Pyelonephritis	1 (0.1)	1
Herpes simple	1 (0.1)	3
Cystitis	1 (0.1)	2
Cutaneous leishmaniasis	1 (0.1)	1
Tinea versicolor	1 (0.1)	1
Yeast infection	1 (0.1)	1
Acarodermatitis	1 (0.1)	1
Pharyngitis	1 (0.1)	1
Influenza	1 (0.1)	1
Vaginal infection	1 (0.1)	1
Hepatobiliary disorders	21 (3.0)	22
Hypertransaminasemia	15 (2.5)	16
Hepatotoxicity	3 (0.4)	3
Liver disorder	2 (0.3)	2
Toxic hepatitis	1 (0.1)	1
Cardiac disorders	12 (1.9)	13
Bradycardia	9 (1.3)	9
Atrioventricular block	3 (0.4)	3
Palpitations	1 (0.1)	1
Investigations	13 (1.9)	14
Increased transaminases	12 (1.7)	14
Nervous system disorders	9 (1.3)	10
Headache	6 (0.9)	7
Dizziness	3 (0.4)	3
Skin and subcutaneous tissue disorders	7 (1.0)	7
Alopecia	5 (0.7)	5
Papulopustular rosacea	1 (0.1)	1
Psoriasis	1 (0.1)	1
General disorders and administration	5 (0.7)	5

site conditions		
Chest pain	2 (0.3)	2
Asthenia	1 (0.1)	1
Fatigue	1 (0.1)	1
Pyrexia	1 (0.1)	1
Gastrointestinal disorders	4 (0.6)	4
Sickness	2 (0.3)	2
Diarrhea	1 (0.1)	1
Dental caries	1 (0.1)	1
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)	3 (0.4)	3
Basal cell carcinoma	1 (0.1)	1
Kidney neoplasia	1 (0.1)	1
Lipoma	1 (0.1)	1
Eye disorders	3 (0.4)	3
Decreased visual acuity	1 (0.1)	1
Retinal alteration	1 (0.1)	1
Macular edema	1 (0.1)	1
Respiratory, thoracic and mediastinal disorders	1 (0.1)	1
Dyspnoea	1 (0.1)	1

3

4